Since the mother is already at the hospital for the baby delivery, she has no choice but to pay the price.

Must of been a great pitch that Navigenics put on MDV.

I can’t imagine that either of these companies is making millions yet.

Both seem like cool ideas to me. Similar but marketing to different groups.

I like the VCs are backing these kind concepts regardless of which it is.

This seems to have worked out poorly for MDV–Navigenics is doing terribly from what I hear, and has been forced to completely change their business model due to lack of customers.

Treatments are great, but we need to start looking at how to prevent a disease from even starting. In general, I tend to lean toward the Navigenics services — they seem more serious and focused on the health and medial application, while 23andme is about having fun with your DNA.

I suppose there is a market for both, but it makes sense that MDV would pull out and get inline with the company that has physician and medical partnership.

Once a baby is born the report is automatically available to parents to look at it and who knows may be to fix also any genetic anomalies.

Two other similar Silicon Valley companies that are even more clinical based than Navigenics (and in my opinion the right strategy) are Counsyl and Gene Security Network.

Your opinion seems to be in agreement with the general opinions and ratings at thefunded.com